StonvexLoading…
StonvexStonvexStonvexCore line items from MED's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $385.79M | $602.46M | $1.07B | $1.60B |
Operating Income | $-14.21M | $2.88M | $126.40M | $184.81M |
Net Income | $-18.67M | $2.09M | $99.42M | $143.57M |
EPS (Diluted) | $-1.70 | $0.19 | $9.10 | $12.73 |
Total Assets | $247.97M | $284.21M | $309.91M | $316.21M |
Total Liabilities | $49.05M | $74.10M | $108.43M | $161.17M |
Cash & Equivalents | $89.30M | $90.93M | $94.44M | $87.69M |
Free Cash Flow OCF − CapEx | $1.25M | $17.02M | $141.17M | $177.89M |
Shares Outstanding | 10.99M | 10.94M | 10.90M | 10.87M |